{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:08:26Z","timestamp":1774328906560,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12032-018-1147-y","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T08:05:35Z","timestamp":1525421135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Check point inhibitors a new era in renal cell carcinoma treatment"],"prefix":"10.1007","volume":"35","author":[{"given":"Mohamed","family":"Alsharedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"issue":"1","key":"1147_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1147_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00002371-199201000-00001","volume":"11","author":"JH Finke","year":"1992","unstructured":"Finke JH, Rayman P, Edinger M, et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8 T cell line. J Immunother. 1992;11(1):1\u201311.","journal-title":"J Immunother"},{"issue":"3","key":"1147_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1147_CR4","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","volume":"338","author":"S Negrier","year":"1998","unstructured":"Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran\u00e7ais d\u2019Immunoth\u00e9rapie. N Engl J Med. 1998;338(18):1272.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"1147_CR5","doi-asserted-by":"publisher","first-page":"iii49iii56","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Schmidinger M, Algaba F, Patard J, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49\u2013iii56. https:\/\/doi.org\/10.1093\/annonc\/mdu259 .","journal-title":"Ann Oncol"},{"key":"1147_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12967-014-0291-1","volume":"12","author":"P Ascierto","year":"2014","unstructured":"Ascierto P, Addeo R, Carten\u00ec G, Daniele B, De Laurentis M, Ianniello, et al. The role of immunotherapy in solid tumors: report from the Campania society of oncology immunotherapy (SCITO) meeting, Naples 2014. J Transl Med. 2014;12:291.","journal-title":"J Transl Med"},{"key":"1147_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803.","journal-title":"N Engl J Med"},{"key":"1147_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol. 2017;72:368\u201376.","journal-title":"Eur Urol"},{"key":"1147_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:962\u201371.","journal-title":"Eur Urol"},{"key":"1147_CR10","unstructured":"Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab versus sunitinib in untreated metastatic renal cell carcinoma. 2018 Genitourinary Cancers Symposium. Abstract 578. Presented February 10, 2018."},{"key":"1147_CR11","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab + ipilimumab vs sunitinib for treatment-na\u00efve advanced or metastatic renal cell carcinoma (RCC): results from CheckMate 214, including overall survival by subgroups (Abstract O38). Society for Immunotherapy of Cancer 2017 meeting, 2017."},{"key":"1147_CR12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/annonc\/mdw373.01","volume":"6","author":"MB Atkins","year":"2016","unstructured":"Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): preliminary safety and efficacy results. Ann Oncol 2016;6:266 (Abstract 773PD).","journal-title":"Ann Oncol"},{"key":"1147_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","volume":"73","author":"T Powles","year":"2017","unstructured":"Powles T, Albiges L, Staehler M, et al. Updated European association of urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2017;73:311\u20135.","journal-title":"Eur Urol"},{"issue":"14","key":"1147_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"key":"1147_CR15","doi-asserted-by":"crossref","unstructured":"Escudier B, Tannir N, McDermott D, et al. Efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-na\u00efve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups (abstract LBA5). Presented at the 2017 European Society of Medical Oncology meeting, 2017.","DOI":"10.1093\/annonc\/mdx440.029"},{"key":"1147_CR16","unstructured":"ClinicalTrials.gov. 2017. Identifier NCT03141177, a study of nivolumab combined with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 9ER), May 4, 2017, [about 4 screens]. Bethesda: National Library of Medicine (US). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03141177?term=checkmate+9ER&cond=Renal+Cell+Carcinoma&rank=1 . Accessed 9 April 2018."},{"key":"1147_CR17","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Powles T, Atkins MD, et al. IMmotion 151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) abstract 578. Presented on 10 February 2018, Genitourinary Cancer Symposium, San Francisco, USA, 2018.","DOI":"10.1200\/JCO.2018.36.6_suppl.578"},{"issue":"Suppl 2","key":"1147_CR18","doi-asserted-by":"publisher","first-page":"P353","DOI":"10.1186\/2051-1426-3-S2-P353","volume":"3","author":"MB Atkins","year":"2015","unstructured":"Atkins MB, Gupta S, Choueiri TK, et al. Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-na\u00efve patients with advanced renal cell carcinoma. J Immunother Cancer. 2015;3(Suppl 2):P353. https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P353 .","journal-title":"J Immunother Cancer"},{"issue":"Suppl 6","key":"1147_CR19","doi-asserted-by":"publisher","first-page":"773PD","DOI":"10.1093\/annonc\/mdw373.01","volume":"27","author":"MB Atkins","year":"2016","unstructured":"Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): preliminary safety and efficacy results. Ann Oncol. 2016;27(Suppl 6):773PD. https:\/\/doi.org\/10.1093\/annonc\/mdw373.01 .","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"1147_CR20","doi-asserted-by":"publisher","first-page":"TPS4595TPS4595","DOI":"10.1200\/JCO.2017.35.15_suppl.9504","volume":"35","author":"JM Robert","year":"2017","unstructured":"Robert JM, Gr\u00fcnwald V, Hutson TE, et al. A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2017;35(15_suppl): TPS4595\u2013TPS4595.","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"1147_CR21","doi-asserted-by":"publisher","first-page":"TPS4594TPS4594","DOI":"10.1200\/JCO.2017.35.15_suppl.4504","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Rini BI, Larkin JMG, et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). J Clin Oncol. 2017;35(15_suppl): TPS4594\u2013TPS4594.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1147-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1147-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1147-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T23:29:49Z","timestamp":1661124589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1147-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1147-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"15 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No animal or human were involved in this study. It is a review article. Institutional Review Board is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"85"}}